Updates

** Shares of Dexcom DXCM.O rise 8.4% to $62.69

** Medical device maker says it agreed to collaborate with Elliott Investment Management, among its largest investors, to identify two new independent board members

** CEO Jake Leach says on an investor call that DXCM is focusing on refreshing its board and seeks to add independent directors with medtech and operations expertise

** With the additions, the board would have appointed six new independent directors since the beginning of 2023 - DXCM

** William Blair says DXCM's investor update was "positive," citing a "firm long-term revenue growth outlook," increased buyback plans and "more color" on its pipeline

** Brokerage says DXCM's collaboration with Elliott Management to strengthen the board "another positive"

** Including session's moves, DXCM down 5.6% YTD